Novel application of proton pump inhibitor for the prevention of colitis-induced colorectal carcinogenesis beyond acid suppression

Cancer Prevention Research

Volumn 3, Issue 8, 2010, Pages 963-974

  Kim, Yoon Jae ^a   Lee, Jeong Sang ^b   Hong, Kyung Sook ^b   Chung, Jun Won ^a   Kim, Ju Hyun ^a   Hahm, Ki Baik ^a,b  

^a Inha University School of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLOOXYGENASE 2; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEPRAZOLE; STROMELYSIN 3; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CELL STRAIN HT29; CHEMOPROPHYLAXIS; COLITIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; COLITIS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; FEMALE; GASTRIC ACID; HT29 CELLS; HUMANS; MICE; MICE, INBRED C57BL; OMEPRAZOLE; PROTON PUMP INHIBITORS;

EID: 77955436212     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0033     Document Type: Article

References (49)

1. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.
2. Lfberg R, Brostrm O, Karln P, et al. Colonoscopic surveillance in long-standing total ulcerative colitis - a 15-year follow-up study. Gastroenterology 1990;99:1021-31.
3. Korelitz BI. Considerations of surveillance, dysplasia, and carcinoma of the colon in the management of ulcerative colitis and Crohn's disease. Med Clin North Am 1990;74:189-99.
4. Rosenstock E, Farmer RG, Petras R, et al. Surveillance for colonic carcinoma in ulcerative colitis. Gastroenterology 1985;89: 1342-6.
5. Cooper HS, Murthy S, Kido K, et al. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000;21:757-68.
6. Itzkowitz S. Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice. J Clin Gastroenterol 2003;36:S70-4.
7. Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994;107:369-78.
8. Karln P, Young E, Brostrm O, et al. Sialyl-Tn antigen as a marker of colon cancer risk in ulcerative colitis: relation to dysplasia and DNA aneuploidy. Gastroenterology 1998;115:1395-404.
9. Yeo M, Kim D, Park HJ, et al. Loss of transgelin in repeated bouts of ulcerative colitis-induced colon carcinogenesis. Proteomics 2006;6: 1158-65.
10. Tagaki T, Naito Y, Okada H, et al. Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxidase-1 via activation of NF-E2-related factor 2 and oxidation of Kelch-like ECH-associated protein 1. J Pharmacol Exp Ther 2009;331:255-64.
11. Becker JC, Grosser N, Waltke C, et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxidase-1 in gastric and endothelial cells. Biochem Biophys Res Commun 2006;345: 1014-21.
12. Yeo M, Kim DK, Han SU, et al. Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesis. Gut 2006;55:26-33.
13. Yeo M, Kim D, Kim Y, et al. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res 2004;10:8687-96.
14. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003; 94:965-73.
15. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004;23:101-17.
16. Kohno H, Yoshitani S, Takashima S, et al. Troglitazone, a ligand for peroxisome proliferator-activated receptor γ, inhibits chemically-induced aberrant crypt foci in rats. Jpn J Cancer Res 2001;92:396-403. (Pubitemid 32427775)
17. Hata K, Yamada Y, Kuno T, et al. Tumor formation is correlated with expression of β-catenin-accumulated crypts in azoxymethane-induced colon carcinogenesis in mice. Cancer Sci 2004;95:316-20.
18. 2 production. Br J Pharmacol 2005;144:338-48.
19. De Milito A, Iessi E, Logozzi M, et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 2007; 67:5408-17.
20. Aggarwal B, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006;72:1605-21.
21. Glauben R, Sonnenberg E, Zeitz M, et al. HDAC inhibitors in models of inflammation-related tumorigenesis. Cancer Lett 2009;280:154-9.
22. Kuroda M, Yoshida N, Ichikawa H, et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med 2006;17:89-93.
23. Sasaki T, Yamaya M, Yasuda H, et al. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol 2005;509:201-10.
24. Suzuki T, Yamaya M, Sekizawa K, et al. Bafilomycin A(1) inhibits rhinovirus infection in human airway epithelium: effects on endosome and ICAM-1. Am J Physiol Lung Cell Mol Physiol 2001;280: L1115-27.
25. Yeo M, Kim DK, Chung IS, Moon BS, Song KS, Hahm KB. The novel acid pump antagonist for anti-secretory action with their peculiar applications beyond acid suppression. J Clin Biochem Nutr 2006;38:1-8.
26. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007;133:748-64.
27. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sorensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population based, case-control study. Gastroenterology 2007;133:755-60.
28. Ambs S, Merriam WG, Bennett WP, et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res 1998; 58:334-41.
29. Onizawa M, Nagaishi T, Kanai T, et al. Signaling pathway via TNF-α/NF-κB in intestinal epithelial cells may be directly involved in colitisassociated carcinogenesis. Am J Physiol Gastrointest Liver Physiol 2009;296:G850-9.
30. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
31. Sohn KJ, Shah SA, Reid S, et al. Molecular genetics of ulcerative colitis-associated colon cancer in the interleukin 2- and β(2)- microglobulin-deficient mouse. Cancer Res 2001;61:6912-7.
32. Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999;117:814-22.
33. Hisamatsu T, Watanabe M, Ogata H, et al. Interferon-inducible gene family 1-8U expression in colitis-associated colon cancer and severely inflamed mucosa in ulcerative colitis. Cancer Res 1999;59: 5927-31.
34. Hussain SP, Amstad P, Raja K, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000;60:3333-7.
35. Okayasu I, Yamada M, Mikami T, et al. Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J Gastroenterol Hepatol 2002;17:1078-83.
36. Fujii S, Fujimori T, Kawamata H, et al. Development of colonic neoplasia in p53 deficient mice with experimental colitis induced by dextran sulphate sodium. Gut 2004;53:710-6.
37. Hu J, Van den Steen PE, Sang QA, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007;6:480-98.
38. Castaneda FE, Walia B, Vijay-Kumar M, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 2005; 129:1991-2008.
39. Medina C, Santana A, Paz MC, et al. Matrix metalloproteinase-9 modulates intestinal injury in rats with transmural colitis. J Leukoc Biol 2006;79:954-62.
40. Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 2006;318:933-8.
41. Naito Y, Takagi T, Kuroda M, et al. An orally active metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice. Inflamm Res 2004;53:462-8.
42. Cooper HS, Murthy SN, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238-49.
43. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
44. Iwamoto M, Ahnen DJ, Franklin WA, et al. Expression of β-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis 2000;21:1935-40.
45. Sparks AB, Morin PJ, Vogelstein B, et al. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58:1130-4.
46. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
47. Tanaka T, Kohno H, Yoshitani S, et al. Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001;61: 2424-8.
48. Humphries A, Wright NA. Colon crypt organization and tumorigenesis. Nat Rev Cancer 2008;8:415-24.
49. Penman ID, El-Omar F, McGregor JR, Hillan KJ, O'Dwyer PJ, McColl KEL. Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats. Gut 1993;34:1559-65.